This time of year I'm always excited about attending the American Diabetes Association (ADA) Scientific Sessions. This year, they will be held in New Orleans from June 10th through 14th. While I'm not able to tell you any secrets—and, frankly, I don't think I know any—I'm going to talk about what I'm looking forward to learning about and a few things I think will be important.
We know that results from the LEADER trial—the cardiovascular outcomes trial for liraglutide—will be presented on June 13. The headline of these results is that they're positive, but we don't know what cardiovascular outcomes were improved in which patients—basically what this looks like. These results will be very, very important to our understanding of the benefits of GLP-1 receptor agonists on cardiovascular outcomes. I love learning that diabetes drugs also benefit cardiovascular outcomes.
Results of EMPA-REG[1] were reported last fall, and empagliflozin was shown to have significant benefits in terms of reduction in cardiovascular events and overall mortality. But that was just the tip of the iceberg. We have lots to learn; more data about empagliflozin and other SGLT2 inhibitors will be presented at this meeting.
In terms of drugs we have on the market, there are going to be some new twists.
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus Clinical Practice Guidelines (SID/AMD, 2022)
Pediatric Type 2 Diabetes Mellitus
COMMENTARY
Wait for It: Diabetes News Eagerly Anticipated
Anne L. Peters, MD
DisclosuresJune 03, 2016
This time of year I'm always excited about attending the American Diabetes Association (ADA) Scientific Sessions. This year, they will be held in New Orleans from June 10th through 14th. While I'm not able to tell you any secrets—and, frankly, I don't think I know any—I'm going to talk about what I'm looking forward to learning about and a few things I think will be important.
We know that results from the LEADER trial—the cardiovascular outcomes trial for liraglutide—will be presented on June 13. The headline of these results is that they're positive, but we don't know what cardiovascular outcomes were improved in which patients—basically what this looks like. These results will be very, very important to our understanding of the benefits of GLP-1 receptor agonists on cardiovascular outcomes. I love learning that diabetes drugs also benefit cardiovascular outcomes.
Results of EMPA-REG[1] were reported last fall, and empagliflozin was shown to have significant benefits in terms of reduction in cardiovascular events and overall mortality. But that was just the tip of the iceberg. We have lots to learn; more data about empagliflozin and other SGLT2 inhibitors will be presented at this meeting.
In terms of drugs we have on the market, there are going to be some new twists.
Medscape Diabetes © 2016 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Wait for It: Diabetes News Eagerly Anticipated - Medscape - Jun 03, 2016.
Tables
References
Authors and Disclosures
Authors and Disclosures
Author
Anne L. Peters, MD
Professor of Clinical Medicine; Director, Clinical Diabetes Programs, Keck School of Medicine, University of Southern California, Los Angeles, California
Disclosure: Anne L. Peters, MD, has disclosed the following financial relationships:
Served as director, officer, partner, employee, advisor, consultant, or trustee for: (current consultant): Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Novo Nordisk
Served as a speaker or member of a speakers bureau for: (current speakers bureau member): Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.
Served as a consultant or ad hoc speaker/consultant for: AstraZeneca Pharmaceuticals LP; Abbott Laboratories; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Dexcom; Medtronic MiniMed, Inc.; Merck & Co., Inc.; Roche; sanofi-aventis